MedTrace Logo

Study to Evaluate the Efficacy and Safety of Aripiprazole

NCT02069977 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2014-03-11

No results posted yet for this study

Summary

* To evaluate the efficacy of flexibly dosed aripiprazole in reducing serious behavioral problems in Asian children and adolescents with a diagnosis of autism spectrum disorder, as measured by change from baseline to endpoint on the irritability subscale of the aberrant behavior checklist (ABC-I).
* To evaluate the long-term safety and tolerability of flexibly dosed aripiprazole in the treatment of serious behavioral problems in Asian children and adolescents with a diagnosis of autism spectrum disorder.

Conditions

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

  • Korea Otsuka International Asia Arab

    collaborator INDUSTRY

  • Yoo-Sook Joung

    lead OTHER

Principal Investigators

  • Yoo-Sook Joung, MD. PhD. · Sumsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Philippines
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02069977 on ClinicalTrials.gov